TL;DR
This study demonstrates that a modified vaccinia virus Ankara (MVA) vector expressing the SARS-CoV-2 spike protein can effectively protect transgenic mice from lethal COVID-19 infection with just one or two doses. The vaccine elicits strong neutralizing antibody and T-cell responses, preventing viral replication in both the upper and lower respiratory tracts and significantly reducing inflammatory cytokine production.
What Problem Does This Paper Address?
The COVID-19 pandemic necessitates the development of safe and effective vaccines. While various vaccine platforms are being explored, including mRNA and adenovirus vectors, there's a continuous need to evaluate alternative vectors like Modified Vaccinia Virus Ankara (MVA). MVA is a replication-deficient, attenuated virus with a proven safety record as a smallpox vaccine, making it an attractive candidate for delivering antigens for other infectious diseases. This paper addresses the question of whether MVA-based vaccines expressing the SARS-CoV-2 spike protein can elicit protective immunity against COVID-19, specifically focusing on its ability to prevent infection and disease in a relevant animal model.
Methods
The researchers engineered several recombinant MVA (rMVA) vectors expressing modified versions of the SARS-CoV-2 spike (S) protein. These modifications included:
- Proline substitutions (2P): To stabilize the prefusion conformation of the S protein, which is crucial for antibody recognition.
- Furin cleavage site mutation (Δfurin): To prevent the S protein from being cleaved into its functional subunits, potentially affecting its presentation.
- Endoplasmic reticulum retrieval signal deletion (ΔERRS): To improve protein secretion and presentation.
- Receptor Binding Domain (RBD) construct: A specific portion of the S protein known to interact with the host cell receptor (hACE2), engineered with signal peptides and transmembrane domains for enhanced membrane anchoring and immunogenicity.
These rMVAs were tested for their ability to express the S protein on infected cells, which was confirmed by Western blotting and flow cytometry. The immunogenicity of these vectors was evaluated in mice (BALB/c and C57BL/6 strains) by intramuscular injection, assessing both binding and neutralizing antibody responses using ELISA and pseudovirus neutralization assays. T-cell responses were measured by stimulating splenocytes with peptide pools derived from the S protein and analyzing for IFN-γ production by CD8+ T cells. Finally, the protective efficacy of the rMVAs was assessed in K18-hACE2 transgenic mice, a model highly susceptible to SARS-CoV-2 infection, by challenging them intranasally with the virus after vaccination and monitoring for morbidity, mortality, viral load, and inflammatory gene expression.
Datasets
Not discussed in the paper. The study primarily uses experimental data generated from mouse models and cell cultures.
Key Insights and Ideas
- MVA as a versatile vaccine vector: The study reinforces MVA's potential as a safe and effective platform for delivering viral antigens, demonstrating its ability to elicit robust immune responses against SARS-CoV-2.
- S protein modifications enhance immunogenicity: Engineering the S protein with proline substitutions and other modifications appears to improve its presentation and immunogenicity, leading to stronger neutralizing antibody titers.
- Single-dose protection is achievable: A significant finding is that even a single vaccination with an rMVA can confer substantial protection against lethal SARS-CoV-2 challenge, with immunity persisting for at least 7 weeks.
- Broad protection against viral replication: The rMVA vaccines not only prevent severe disease but also effectively inhibit viral replication in both the upper (nasal turbinates) and lower (lungs) respiratory tracts.
- Aborted replication in immunized animals: The detection of low levels of viral RNA in the nasal turbinates of vaccinated mice, but no infectious virus, suggests that replication is initiated but quickly aborted, preventing widespread infection.
- Th1-biased immune response: The rMVA vaccines induce a predominantly Th1-biased immune response, characterized by IgG2a/IgG2c antibody subclasses, which is generally associated with effective viral clearance.
Key Results
- Antibody Production: rMVAs expressing modified S proteins induced high titers of neutralizing antibodies (NT50 > 10³) in mice, comparable to levels seen with other vaccine candidates.
- T-cell Response: Vaccination with rMVAs stimulated S-specific CD8+ IFN-γ+ T cells, indicating a cellular immune component to the protection.
- Protection in Transgenic Mice: K18-hACE2 transgenic mice vaccinated with one or two doses of rMVA (specifically the 2P and Tri constructs) were fully protected from morbidity and mortality following intranasal SARS-CoV-2 challenge.
- Viral Load Reduction: No infectious SARS-CoV-2 was detected in the lungs of vaccinated mice, and viral loads in nasal turbinates were significantly reduced or undetectable.
- Reduced Inflammation: Vaccinated mice showed a substantial reduction (approximately three logs) in the expression of key inflammatory cytokines (IFN-β, IFN-γ, TNF-α, IL-6, CXCL10) in the lungs.
- Single-Dose Efficacy: A single rMVA vaccination protected mice from severe disease and viral detection in lungs and turbinates up to 7 weeks post-vaccination.
- Passive Transfer Protection: Transfer of immune serum from vaccinated mice was sufficient to protect naive hACE2 mice from lethal SARS-CoV-2 infection, highlighting the critical role of antibodies.
Limitations and Future Work
- Animal Model Limitations: The K18-hACE2 transgenic mouse model, while useful, may not perfectly recapitulate human COVID-19 disease, particularly regarding the high viral inoculum used, which likely exceeds typical human exposure. Pulmonary function tests and histological examinations were not performed to fully assess pathology.
- Potential Impact of Pre-existing Immunity: The authors acknowledge the potential for pre-existing immunity to vaccinia virus (from smallpox vaccination) to affect immune responses to MVA-based vaccines. However, they cite previous studies in non-human primates suggesting this may not be a significant impediment.
- Route of Administration: While intramuscular (IM) administration was used, the authors suggest that intranasal (IN) administration might be more effective in reducing viral spread in the upper respiratory tract, given MVA's ability to be delivered via this route.
- Optimization of Boosts: The study notes that while RBD protein boosts antibody responses, it may not significantly enhance T-cell responses compared to rMVA boosts. Further optimization of prime-boost strategies, including heterologous prime-boosts with MVA and other platforms, is suggested.
- Duration of Immunity: While immunity was shown to persist for at least 7 weeks, longer-term studies would be beneficial to determine the durability of protection.
Summary updated